O'Brien Susan, Giles Francis J
Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Drugs Today (Barc). 2003 Jul;39(7):541-50. doi: 10.1358/dot.2003.39.7.799444.
MoAb-based therapies are evolving into the first broad-spectrum class of targeted anti-leukemic therapy. Developments in many areas, including computer modeling of receptors and ligands, and increasing sophistication in recombinant technologies may result in a rapid increase in the number and complexity of MoAb available. We can anticipate an increase in the number of safer conjugates being delivered to leukemia cells. Further understanding of the in-vitro mechanisms involved in tumor cell killing by MoAb will be important in maximizing the efficacy of this approach.
基于单克隆抗体的疗法正在演变为首个广谱类靶向抗白血病疗法。许多领域的进展，包括受体和配体的计算机建模以及重组技术的日益成熟，可能会导致可用单克隆抗体的数量和复杂性迅速增加。我们可以预期，输送到白血病细胞的更安全偶联物数量将会增加。进一步了解单克隆抗体杀伤肿瘤细胞的体外机制，对于最大化这种方法的疗效至关重要。
